Sean Smith
Plus aucun poste en cours
Historique de carrière de Sean Smith
Anciens postes connus de Sean Smith
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| APTEVO THERAPEUTICS INC. | Comptroller/Controller/Auditor | 01/04/2017 | 01/08/2019 |
| NEUROGENE INC. | Comptroller/Controller/Auditor | 01/10/2019 | 31/03/2023 |
| Director of Finance/CFO | 31/03/2023 | - |
Formation de Sean Smith
| University of Washington | Masters Business Admin |
| University of North Texas | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
| Graduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APTEVO THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
- Bourse
- Insiders
- Sean Smith
- Expérience
